Studieoverzicht
Study name: Amgen Tarlatamab - Dellphi304
Histology | SCLC | ||
---|---|---|---|
Tumor stage | Stage III - IV | ||
Host / recruiting site 1 | LUMC | Enrollment | Closed |
Therapy line | Later line (≥2L) | ||
Design |
Open label, gerandomiseerde fase 3 studie |
||
Intervention | Tarlatamab vs Topotecan |
||
Key outcome parameters | Primaire eindpunt: OS |
||
Key inclusion criteria | Histologisch of cytologisch bevestigd relapse SCLC na 1 lijn platinum-bevattend regime |
||
Key exclusion criteria | Onbehandelde of symptomatische CNS metastasen of leptomeningeale metastasen |
||
Contact information | Log in voor de contactinformatie |